Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...
Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results